These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29229582)

  • 1. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
    Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients.
    Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
    Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
    Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
    Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma.
    Marchioni M; Harmouch SS; Nazzani S; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Cancer Epidemiol; 2018 Jun; 54():112-118. PubMed ID: 29715680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy.
    Cano Garcia C; Flammia RS; Piccinelli M; Panunzio A; Tappero S; Barletta F; Incesu RB; Law KW; Morra S; Tian Z; Saad F; Kapoor A; Shariat SF; Longo N; Tilki D; Briganti A; Terrone C; Antonelli A; De Cobelli O; Hoeh B; Kluth LA; Chun FKH; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Feb; 22(1):1-6. PubMed ID: 37344282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.
    Marchioni M; Preisser F; Bandini M; Nazzani S; Tian Z; Kapoor A; Cindolo L; Abdollah F; Tilki D; Briganti A; Montorsi F; Shariat SF; Schips L; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):467-473. PubMed ID: 29398456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma.
    Palumbo C; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Dzyuba-Negrean C; Shariat SF; Saad F; Simeone C; Berruti A; Briganti A; Kapoor A; Antonelli A; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Dec; 18(6):e730-e738. PubMed ID: 32800473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Survival in Contemporary Community-Based Patients With Metastatic Clear-Cell Renal Cell Carcinoma Undergoing Active Treatment.
    Incesu RB; Morra S; Scheipner L; Baudo A; Jannello LMI; de Angelis M; Siech C; Assad A; Tian Z; Saad F; Shariat SF; Chun FKH; Briganti A; de Cobelli O; Carmignani L; Ahyai S; Longo N; Tilki D; Graefen M; Karakiewicz PI
    J Natl Compr Canc Netw; 2024 Jun; 22(6):390-396. PubMed ID: 38838708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities.
    Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Nazzani S; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
    Cancer Causes Control; 2020 Mar; 31(3):263-272. PubMed ID: 31993859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A non-cancer-related survival benefit is associated with partial nephrectomy.
    Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
    Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients.
    Incesu RB; Barletta F; Garcia CC; Scheipner L; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Carmignani L; Longo N; Ahyai S; Chun FKH; Briganti A; Tilki D; Graefen M; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Apr; 22(2):420-425. PubMed ID: 38307818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity.
    Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    Urol Oncol; 2022 Nov; 40(11):493.e9-493.e16. PubMed ID: 35907705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy.
    Trinh QD; Sukumar S; Schmitges J; Bianchi M; Sun M; Shariat SF; Sammon JD; Jeldres C; Zorn KC; Perrotte P; Graefen M; Rogers CG; Peabody JO; Menon M; Karakiewicz PI
    Ann Surg Oncol; 2013 Jun; 20(6):2096-102. PubMed ID: 23263779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
    Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
    Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma.
    Mazzone E; Nazzani S; Preisser F; Tian Z; Marchioni M; Bandini M; Capitanio U; Kapoor A; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; I Karakiewicz P
    Cancer Epidemiol; 2018 Oct; 56():118-125. PubMed ID: 30173050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT
    Marchioni M; Bandini M; Pompe RS; Martel T; Tian Z; Shariat SF; Kapoor A; Cindolo L; Briganti A; Schips L; Capitanio U; Karakiewicz PI
    BJU Int; 2018 Mar; 121(3):383-392. PubMed ID: 28940649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.